跳至主要内容
临床试验/NCT00631150
NCT00631150已完成4 期

A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

UCB Pharma0 个研究点目标入组 35 人开始时间: 2003年3月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
UCB Pharma
入组人数
35
主要终点
Safety and the tolerability of Keppra in a broad population of patients.

研究概览

简要总结

Patients in community-based practices correspond to the 25% of patients who need a first add-on drug when not controlled by their standard monotherapy drug. This was a therapeutic use trial in which the population corresponds more closely to that seen in daily clinical practice.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • partial onset seizures with or without secondary generalisation with epilepsy.

排除标准

  • hypersensitivity to levetiracetam or other pyrrolidone derivatives or to any of the excipients.

结局指标

主要结局

Safety and the tolerability of Keppra in a broad population of patients.

次要结局

  • Obtain further information about optimal daily dose.

研究者

发起方
UCB Pharma
申办方类型
Industry

相似试验